In this episode of the IMF’s #AskDrDurie web series, Dr. Brian G.M. Durie talks about when and for what kind of myeloma patient an autologous stem cell transplant (ASCT) is recommended.


Image of Dr. Brian G.M. DurieDr. Brian G.M. Durie serves as Chairman of the International Myeloma Foundation and serves on its Scientific Advisory Board. Additionally, he is Chairman of the IMF's International Myeloma Working Group, a consortium of nearly 200 myeloma experts from around the world. Dr. Durie also leads the IMF’s Black Swan Research Initiative®.

Previous Post
#AskDrDurie: What is Selinexor?
Next Post
#AskDrDurie: Has there been any change in recommendations used to treat bone disease in myeloma?

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.